Chronic lymphocytic leukemia (CLL) clones are characterized by loss of a critical region in 13q14.3, (del(13)(q14)) involving the microRNA (miRNA) cluster miR-15a and miR-16-1. We have investigated the effects of replacement of miR-15a and miR-16-1. CLL cells transfected with these miRNA mimics exhibited a decrease in cell viability in vitro and impaired capacity for engraftment and growth in NOD/Shi-scid,γcnull (NSG) mice. No synergistic effects were observed when the two miRNA mimics were combined. The phenomena were not restricted to CLL with the del(13)(q14) lesion. Similar effects induced by miRNA mimics were seen in cells with additional chromosomal abnormalities with the exception of certain CLL clones harboring TP53 alterations. Administration of miRNA mimics to NSG mice previously engrafted with CLL clones resulted in substantial tumor regression. CLL cell transfection with miR-15a and miR-16-1-specific inhibitors resulted in increased cell viability in vitro and in an enhanced capacity of the engrafted cells to grow in NSG mice generating larger splenic nodules. These data demonstrate that the strong control by miR-15a and miR-16-1 on CLL clonal expansion is exerted also at the level of full-blown leukemia and provide indications for a miRNA-based therapeutic strategy.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is characterized by the monoclonal expansion of B cells expressing CD19, CD5 and CD23 and low levels of surface immunoglobulin. 1 The mechanisms underlying the disease have only been partially elucidated. In CLL, well-defined chromosomal abnormalities, such as deletions at (17) (p13.1), (11)(q22.3) or trisomy 12 (+12) are infrequent at early stages and more common in patients with more advanced disease or at relapse. Therefore, these lesions are unlikely to contribute to the initial pathogenetic mechanisms, although they may be involved in both disease progression and resistance to therapy. [2] [3] [4] [5] [6] [7] [8] The 13q14.3 (del(13)(q14)) deletion represents a remarkable exception, as it is observed in approximately 50% of cases either in a mono-or biallelic form and is also present in the early disease stages, 4, 9 including monoclonal B cell lymphocytosis or MBL, 10, 11 suggesting a pathogenetic role. The deletion identified involves primarily the DLEU2 gene which carries the locus of two microRNAs (miRNAs): miR-15a and miR-16-1 (miR-15 and miR-16, respectively). [12] [13] [14] [15] [16] [17] MiRNAs are single stranded, non-coding RNA, which are evolutionary conserved and capable of regulating the expression of several genes concomitantly. 18 The regulation of gene expression occurs mainly through the specific binding of miRNAs to the 3′-un-translated region (3′-UTR) of the messenger RNA of the target gene via a RNA-induced silencing complex, 19 although additional mechanisms have been described. 20 Biallelic del(13)(q14) results in an incapacity of the cell to express miR-15 and miR-16 14, 15, 17, 21, 22 (Supplementary Figure S1 ) and the deregulation of several target genes, including those involved in cell cycle progression and apoptosis. [23] [24] [25] This confers an increased resistance to apoptosis and a propensity to leukemic cell proliferation. Low levels of miR-15 or miR-16 are observed in patients with monoallelic deletions and in many patients without del(13)(q14). 15, 21, 22, [26] [27] [28] Additional support for the role of the miR-15/miR-16 locus in CLL pathogenesis comes from the New Zealand Black (NZB) mice strain harboring a germ-line point mutation downstream of the miR-16 locus, which prevents normal expression of both miR-15 and miR-16 and facilitates leukemia onset and possibly autoimmune manifestations. 29 An analogous lesion, present in particular families, genetically predisposes humans to CLL and possibly to other neoplasias. 30 Finally, the selective deletion of the miR-15/miR-16 locus in mice predisposes the development of a CLL-like leukemia. 16, 31 Therefore, impairment of miR-15 and miR-16 function may be involved in promoting the initial phases of leukemogenesis; however, little is known regarding the role of these lesions in maintaining the transformed status and the clonal expansion of full-blown leukemia. 32 Here, we investigated the possibility of interfering with both miR-15 and miR-16 expression by CLL cells, both in in vivo and in vitro.
MATERIALS AND METHODS

Patients and CLL cell preparations
Newly diagnosed CLL patients from participating Institutions were enrolled within 12 months from diagnosis in the O-CLL1 protocol (clinicaltrial.gov identifier NCT00917540). All participants provided written informed consent in accordance with the declaration of Helsinki and the study was approved by the appropriate institutional review boards. Supplementary Table S1 summarizes the phenotype and the major cytogenetic features of CLL cases (n = 59) selected for in vitro (n = 48) and in vivo (n = 17) experiments reported in this study. 11, 33, 34 PBMCs from patients with CLL were isolated by Ficoll-Hypaque (Seromed, Biochrom, Berlin, Germany) density gradient centrifugation. In selected experiments, CD19-positive CLL cells were enriched by negative selection with the EasySep-Human B-cell Enrichment Kit without CD43 depletion (STEMCELL Technologies, Voden Medical Instruments S.p.A, Milan, Italy).
Cell transfection
MirVana miRNA mimics or inhibitors (Ambion, Inc., Thermo Fisher Scientific, Grand Island, NY, USA) were delivered to CLL cells with a Neon Transfection System (Invitrogen, Thermo Fisher Scientific) at the final concentration of 50 nM/2 × 10 6 CLL cells. Optimal transfection and survival of CLL cells was obtained by applying 1 pulse at 2150 pulse voltage and 20 pulse width, as indicated by the manufacturer for the primary bloodderived suspension cells protocol. After transfection, cell suspensions were seeded in 24-well plates containing 500 μl of culture medium without antibiotics (RPMI-1640 with L-glutamine and 10% FBS (Gibco, Thermo Fisher Scientific, Paisley, UK), Sodium piruvate 0.1% (Euroclone, Pero, Milan, Italy) at 37°C and incubated at the final concentration of 2 × 10 6 CLL cells/ ml/well in a 5% CO2 atmosphere. The following miRNA mimics and inhibitors were employed: hsa-miR-15a-5p, hsa-miR-16-5p, and miRNA Negative Control (CTR)#1, miRNA Inhibitor Negative CTR #1.
Evaluation of miRNA expression
MiR-15 and miR-16 expression was evaluated with two methods: SmartFlare RNA Detection Probes (Merck Millipore, Guyancourt, France) in n = 13 CLL cases and quantitative real time PCR (qRT-PCR; n = 38 CLL cases; Supplementary materials and methods and Supplementary Figure S2 ).
SmartFlare technology is useful to study miRNA expression at the singlecell level. SmartFlare RNA Detection Probes, are constituted by tiny gold nanoparticles conjugated to oligonucleotides duplexed with reporter strands (oligo+fluorophore). When Smartflare probes bind to their complementary RNA sequences the fluorophore is released and can be detected by flow-cytometry (FC). The following Smartflare probes conjugated with the Cyanine 5 (Cy5) fluorophore were used: SF-430/ miR-15a-5p (miR-15 CY5); SF-178/ miR-16-5p (miR-16 CY5); SF-102/ Scramble CTR Cy5. The latter reagent does not bind to any RNA sequences within the cells and is used to measure the level of background fluorescence within CLL cells. Cells were incubated with Smartflare probes overnight, harvested and analyzed by FACSCanto (BD Biosciences, San José, CA, USA) and DIVA 6 (BD Biosciences) or FLOWJO V.9.8.3 software (Treestar, Inc., Ashland, OR, USA).
Counter staining with propidium iodide (PI; 50 mg/ml, Sigma-Aldrich, Milan, Italy) in isotonic solution was employed to evaluate cell viability.
Changes 36, 37 were housed in sterile enclosures under specific pathogen-free conditions. All procedures involving animals were performed in the respect of the current National and International regulations and were reviewed and approved by the Licensing and Animal Welfare Body of the IRCCS-AOU San Martino-IST National Cancer Research Institute, Genoa, Italy.
Depending on the number of leukemic cells available for animal injection, groups of 2-3 NSG mice were employed for each test and treatment group. The number of animals used for each treatment is detailed in brackets in Table 1 and Supplementary Tables S3-S5 . Full details are in Supplementary Material and Methods.
In miRNA pre-treatment experiments NSG mice (n = 38) were inoculated with CLL cells (n = 6) transfected with miRNA mimic/inhibitors and cultured for 6 h prior to injection. A total of 50 × 10 6 CLL cells per mouse were injected together with a proportion of autologous T cells (~5-10%).
After four weeks, mice were anesthetized by intraperitoneal injection of combination of xylazine (10 mg/kg) and ketamine (100 mg/kg) and analyzed by Magnetic Resonance Imaging (MRI) with USPIO contrast reagent. 38 On termination of the experiment (maximum 6 weeks from start), animals were sacrificed in a saturated CO2 chamber and autopsies were performed. Spleens were evaluated by FC and by immunohistochemical (IHC) analysis. The Animal Welfare Body posed a time limit to the experimental protocol to prevent unneeded suffering.
Fresh spleen samples were enzymatically digested using the Spleen Dissociation Kit (Miltenyi Biotec) and mechanically resuspended with gentleMACS™ Dissociator (Miltenyi Biotec). The single-cell suspensions were stained with anti-human CD45-FITC (555482), CD19-PECy7(557835), CD5-APC(555355), (BD Biosciences) and analyzed by FC. Apoptosis was evaluated using Annexin-V-FITC, CD19-PE-Cy7, CD5-PE (555353) (BD Biosciences), CD45-APC(130-091-230, Miltenyi Biotec,) cell staining.
Formalin-fixed and paraffin-embedded spleen specimens were analyzed for the presence of human CLL infiltrates and for the presence of coinjected bystander T-cells by IHC as detailed above. 38 The primary antibodies anti-CD20 Mouse monoclonal antibody (760-2531, clone L26-Ventana Medical System, Roche) and CD3 Rabbit Monoclonal Antibody (790-4341, clone 2GV6-Ventana Medical System, Roche) were incubated for 30 min at 37°C and signals revealed using the polymeric detection system, Ultraview Universal Red Detection Kit (Ventana Medical System). An appropriate positive tissue control was used for each staining run; the negative control consisted of performing the entire IHC procedure on adjacent sections in the absence of the primary antibody; the sections were counter-stained (automatically) with Gill's modified hematoxylin and then cover-slipped. The sections were evaluated by two observers with an Olympus light microscope using 4, 10, 40 × and objectives under a Leica DMD108 optical digital microscope (Leica Microsystems, Wetzlar, Germany).
To evaluate therapeutic effects of miRNA, CLL (n = 11) engraftment in the spleen was determined by MRI following USPIO contrast reagent injection after 2-3 weeks from cell injection. At this stage, mice were treated intraperitoneally (every second day with mirVana miRNA mimic, (In Vivo Ready formulation, Ambion, Inc.) complexed with Invivofectamine 2.0 (Thermo Fisher Scientific) at a final concentration of 0.7 mg/ml (200 μl/mouse). Overall three doses were administered. The following miRNA were used: hsa-miR-15a-5p, hsa-miR-16-5p, miRNA negative control#1. Three days from the last injection, mice (n = 74) were analyzed again by MRI and then sacrificed in a saturated CO2 chamber and autopsies were performed. Spleens were analyzed by FC and IHC. Apoptosis was evaluated by Annexin-V-FITC, CD19-PE-Cy7, CD5-PE, CD45-APC, and FC or by Cleaved Caspase-3 (Asp175) (5A1E) Rabbit mAb (9664, Cell Signaling Technology, Danvers, MA, USA) and IHC on spleen tissue sections.
Magnetic resonance imaging
All in vivo MRI experiments and MRI analyses, using USPIO nanoparticles, were carried out and acquired as previously described. 38 Details are reported in the Supplementary Information.
Definition of IHC index
The IHC index is a measure of the spread of leukemia based on the average diameters of the follicular lesions. We assigned a numerical value of 1 to the follicles with diameters ± s.d. of 102(±90) × 42(±7) μm; a value of 3 to follicles with a diameter 195(±80) x 138(±85) μm; a value of 6 to follicles between 399(±245) × 300(±39), and a value of 12 to follicles between 734 (±461) × 540(±167). The IHC index is given by the sum of the number of follicles multiplied by the value assigned according to size (Supplementary Figure S3 ).
Statistical analysis
The statistical package SPSS for Windows, v13.0, 2004 software (SPSS, London, UK) was used for all analyses of statistical significance from adequately powered sample sizes for two-tailed tests. Statistical comparisons between related samples were carried out by nonparametric Wilcoxon signed rank (paired data) or by Mann-Whitney U-(unpaired data) tests. A value of P o0.05 was considered significant for all statistical calculations. Values are given as mean ± s.e.m. or mean ± s.d. as stated in figure legends, which was calculated invariably from n (the number of patients or animals, biological replicates). All exact P-values are provided in the figure panels, in figure legends or in Results section.
RESULTS
Transfection of miR-15 and miR-16 mimics or inhibitors into CLL cells in vitro
Transfection of miRNAs mimics or inhibitors into purified CLL cells was verified by FC using Smartflare technology and qRT-PCR.
For the experiments with miRNA mimics, 7 CLL cases with biallelic del(13)(q14) deletions were selected (Supplementary  Information and Supplementary Table S1 for case characteristics). At 24 h after transfection, a significantly larger number of cells were found to express miR-15 (%fold induction = 79 ± 5, mean ± s.e.m.) and miR-16 (%fold induction = 75 ± 5) compared with control preparations (P = 0.015; Figure 1a and Supplementary Figure S4a) . Comparable data were obtained by qRT-PCR (Supplementary Figure S2a) .
For experiments with miRNA inhibitors, we selected 6 CLL cases that did not display biallelic del(13)(q14) and expressed miR-15 and miR-16 to a variable extent. Transfection with specific miRNA inhibitors efficiently reduced miRNA expression in all CLL clones 2) or miR-16 (49.1 ± 7.6) or miR-CTR mimics (10.9 ± 2.2 for miR-15; 10.8 ± 1.9 for miR-16) determined by smartflare technology. Summary of tests on 7 CLL cases with biallelic del(13)(q14) (MG0248, DT0300, MA0088, LD0062, GM0041, RD0296 and GD0051). (b) Summary of viability determinations obtained on cells from 12 different biallelic del(13)(q14) CLL cases after a 48-h culture following transfection of the indicated miRNA mimics (data for individual cases are reported in Supplementary Figure S6a) . The asterisks indicate data from a CLL case (CG0620) harboring the TP53 mutation (Supplementary Table S1 ). Therapeutic approach with miR-15 and -16 in chronic lymphocytic leukemiacompared with controls (%fold inhibition = 54 ± 4, mean ± s.e.m., for miR-15; and %fold inhibition = 59 ± 4 for miR-16) (P = 0.03) (Figure 1c and Supplementary Figure S4b) . Again, comparable data were obtained when miRNA expression was measured by qRT-PCR (Supplementary Figure S2b) .
As miR-15 and miR-16 expression may impact on CLL cell survival in vitro, purified cells from 12 CLL cases with biallelic del (13)(q14) were transfected with miR-15 or miR-16 miRNA mimics and cultured for up to 72 h. Viable cells were measured at different time intervals (Supplementary Figure S5a shows the data of a representative experiment). A significant decrease in cell viability (%fold reduction mean ± s.e.m. = 53 ± 7 and 48 ± 6 for miR-15 and miR-16 mimics, respectively in 11/12 CLL samples) after 48 h (P = 0.001 for miR-15 and P = 0.0015 for miR-16) was observed. Figure 1b shows the pooled data from the tests performed while experiments on individual CLL cases are reported in Supplementary Figure S6a . Viability of cells from the CLL case CG0620, carrying a TP53 mutation, did not change, but the cells from two other CLL cases (MG0248, PA0254), also displaying TP53 mutations, showed a substantial drop in cell viability following Figure S8) . (e) Pooled flow-cytometry data obtained from 4 CLL cases with biallelic del(13)(q14) pre-treated with miRNA mimics in vitro before injection into mice (n = 8 mice for each treatment group). The cells, harvested from mice at the end of tests, were stained and counted. Statistical comparisons were carried out using Wilcoxon-matched pair test. A P-value = 0.0078 is indicated by **. (f) Pooled flow-cytometry data on cells from 2 CLL cases with normal FISH pre-treated in vitro with miRNA inhibitors prior to injection into mice (n = 5 mice for miR-CTR, n = 4 for miR-15 and n = 5 for miR-16 inhibitors). *P = 0.016 and **P = 0.007, respectively (Mann-Whitney U-test). In e and f values are expressed as mean ± s.d. and detailed in Supplementary Table S3 . Table S1 and Supplementary Figure S6a) .
Co-transfection of biallelic del(13)(q14) CLL cells with both miR-15 and miR-16 miRNAs never resulted in an additive/ synergistic effect (data not shown). Consistent with previous observations, transfection of miR-15 or miR-16 into del(13)(q14) CLL cells caused down-regulation of BCL-2 or MCL1 (antiapoptotic) and of Cyclin D1 or D2 (cell cycle induction) proteins encoded by target genes of these miRNAs. 23, 24 In contrast, Survivin, which is involved in an alternative apoptotic pathway, was not downregulated (Supplementary Figure S6b-c) .
Inhibition of miR-15 or miR-16 expression with specific miRNA inhibitors resulted in a substantial increase in CLL cell viability.
Supplementary Figure 5b reports the cell viability of a representative CLL case. A significant increase in cell viability was measured until 48-hours culture, whereas at 72 h, a drop in cell viability was observed both in the presence of miR-15/miR-16 inhibitors and in the presence of miR-CTR inhibitor, although there were still differences in the two conditions. Pooled viability data, measured after a 48-h culture from a group of 24 CLL cases displaying different cytogenetic features (Supplementary Table S2 and Supplementary Figure S7) , are summarized in Figure 1d (%fold increase = 40 ± 3 and 42 ± 4 with miR-15 or miR-16 inhibitor, respectively; P o 0.0001) and show that miRNA inhibition expression resulted consistently in a better in vitro survival of CLL cells. 38 Iron uptake is inversely correlated with the presence of CLL follicles-like structures which prevent iron uptake. Signal-to-Noise ratio change (ΔSNR%) values are higher when low iron levels enter the splenic tissue. Thus, higher uptake of the USPIO contrast reagent was observed in the spleens of NSG mice receiving CLL cells transfected with miR-15 or miR-16 mimics which resulted into a lower ΔSNR% value compared with the spleens of mice receiving miR-CTR-transfected CLL cells (Figure 2a) . The ΔSNR% of mice injected with miR-15 (mean ± s.d. = − 31.1 ± 25.1) or miR-16 (mean ± s.d. = − 18.2 ± 28.19) mimics pre-treated cells resembled that of NSG mice that had not received leukemic cells (mean ± s.d. = − 54.3 ± 15), whereas this value was higher (+30.7 ± 23.4) in the mice receiving miR-CTR pre-treated cells. ΔSNR% values of mice groups pre-treated with miR-15 (n = 7) or with miR-16 (n = 6) were significantly lower compared with those pre-treated with miR-CTR (n = 8; P = 0.001 for miR-15; P = 0.01 for miR-16). This MRI Table S5 . Figure S8a) . B cells recovered from NSG mice consistently shared the same BCR gene rearrangements as the leukemic clone used for injection, whereas T cells displayed oligoclonal TCR rearrangments (data not shown).
Cells from two CLL cases (PM0608, PA0145) lacking del(13)(q14) were pre-treated with miR-15 or miR-16 inhibitors in vitro and subsequently injected into NSG mice together with T cells according to the same schedule described above. This treatment resulted in a better splenic engraftment of the CLL cells as documented by the differences in the ΔSNR% (Figure 2b ). In the spleen of mice injected with the cells from PM608 CLL case, these values were of +49 ± 8.4
and +33 ± 19.3 after pre-treatment of the cells with miR-15 and miR-16 inhibitors, respectively and of +8 ± 11.1 after cell pretreatment with miR-CTR inhibitors. This was paralleled by an average IHC index increase (mean ± s.d.) of 69 ± 6% and 71 ± 17% respectively, in mice inoculated with miR-15 or miR-16 inhibitor pre-treated cells (P = 0.039 for miR-15 and P = 0.05 for miR-16 inhibitors compared with miR-CTR inhibitor, Figure 2d ). Consistent with these data was the significant increase in the percentage of CD45+CD19 +CD5+ cells observed by FC in the mice inoculated with miRNA inhibitor-treated cells (71 ± 3% and 69 ± 1%, mean ± s.d., respectively) (Figure 2f, and Supplementary Figure S8b) . All data are detailed in Supplementary Table S3 . Again, the BCR and TCR gene rearrangement analyses confirmed that the engrafted B cells were mostly from the leukemic clones, whereas T cells were oligoclonal (not shown).
Inhibition of CLL cell expansion in NSG mice by treatment with miR-15 and miR-16 mimics Next, we investigated whether administration of miRNA mimics could inhibit the expansion of a previously inoculated CLL clone in NSG mice. In preliminary tests, six NSG mice were injected with MG0248 CLL cells. After four weeks, a single potentially therapeutic dose of miR-15 miR-16 or miR-CTR complexed with Invivofectamine was administered intraperitoneally. Mice were sacrificed 24-h after miRNA administration and CLL cells (CD45+, CD19+ and CD5+) were purified by FACS sorting from splenic cell suspensions (the resulting preparations contained 498% CLL cells). qRT-PCR analysis showed an increase of miR-15 (fold increase = 407.80) and of miR-16 (fold increase 34.15) levels above control mice injected with miR-CTR (Supplementary Figure S9) .
Next, CLL cells from six cases with biallelic del(13)(q14) were inoculated into NSG mice together with T cells (NSG-CLL) and CLL engraftment was verified in the spleen after approximately two weeks by MRI. 38 Mice found to have an above-average splenic ΔSNR%, compared with NSG mice that had not received leukemic cells (NSG-CTR, n = 12, ΔSNR% − 54.3 ± 15, mean ± s.d.), were placed on treatment with miR-15 or miR-16 mimics or miR-CTR (one injection on alternate days for a total of three injections). Three days after the final treatment, splenic infiltration by leukemic cells was evaluated (Figures 3 and 4) . On MRI (exemplified in Figure 3a and b) , miR-CTR treated mice displayed a splenic infiltration by leukemic cells with an 63 ± 14 average increase of ΔSNR% over that of mice not receiving leukemic cells (P o 0.0001). In contrast, mice treated with miR-15 or miR-16 mimics showed a significant ΔSNR% decrease (P o 0.0001 and P = 0.0002, respectively) compared with mice before therapy administration (Figure 3c) . The values of the treated mice were similar to those of NSG-CTR mice not receiving CLL cell inocula.
The ΔSNR% values of mice treated with miR-CTR following CLL cell inoculation were similar to or greater than those at therapy start time point (P = 0.002; Figure 3c ). These results predicted a response to therapy, which was subsequently confirmed by FC analysis (average percentage CLL cells reduction of 61 ± 8 (P = 0.0006) and of 75 ± 12 (P = 0.0001) after miR-15 and miR-16 mimics treatment, respectively, vs. mice treated with miR-CTR; Figure 3d ) and IHC. A significantly lower IHC index was observed in mice treated with miR-15 or miR-16 compared with mice treated with miR-CTR (average IHC index reduction 62 ± 15 (P = 0.0007) and 78 ± 22 (P = 0.02), respectively) ( Figure 3e and Supplementary Table S4) .
IHC analysis showed an almost complete disappearance of the typical aggregates of leukemic (CD20+) cells after treatment with miR-15 or miR-16 mimics (Figure 4a and Supplementary Figure S3b ). However, autologous T cells (CD3+ cells), surrounding what was presumably the area of the previously existing CLL cell aggregates/nodules, were still present in a substantial number, possibly indicating that T cells were not affected by treatment (Figure 4b) . Cleaved CASP3 could be observed in the 'empty nodules' possibly indicating apoptotic leukemic cells (Figure 4c and Supplementary Figure S10 Figure S2c) . Cell viability was significantly decreased following transfection in most cases (P o 0.001, Figures 5a and b) . Decreased cell viability also was observed when the two major CLL groups were analyzed separately: ie, those with monoallelic del(13)(q14) (statistically significant differences in the miR-15-mimic (P = 0.01), miR-16-mimic (P = 0.005) -treated cells compared with controls) and the group with normal FISH (P = 0.004).
In addition, viability of the cells from other cases, including one with del(11)(q22.3), involving the ATM gene, and others with p53 mutations or del(17)(p13.1) was reduced following miR-15 and miR-16 mimic transfection.
Finally, NSG mice were engrafted with cells from two cases harboring monoallelic del(13)(q14) (FP0499, GN0095), one case with trisomy 12 (RD0468), one with a normal FISH pattern (VS0624) and one with del(17)(p13.1) and a TP53 mutation on the remaining allele (RM0626), and were subsequently treated with miR-15 or miR-16 as above. A significant reduction of splenic disease was observed by FC (P = 0.0001 and P = 0.006 following miR-15 or miR-16 mimic treatment, respectively compared with miR-CTR; Table 1 ). A decrease in the IHC index of 72 ± 18% and 74 ± 10% following treatment with miR-15 and miR-16 mimics, respectively (P = 0.001) was observed in four of the CLL cases tested. Case RM0626 represented a remarkable exception, as treatment with the miRNA mimics consistently failed to significantly block the growth of CLL cells in vivo. Of note is the finding that this case had low miR-15 and medium to high miR-16 expression. Thus, the findings were unlikely related to the possibility that the miRNA values were already so high that could not be changed by the transfection. Rather, a completely dysfunctional TP53 was the possible cause for the findings.
DISCUSSION
This study demonstrates that in vitro transfection of miR-15 and miR-16 mimics into CLL cells with del(13)(q14) results in a significant inhibition of their subsequent growth in NSG mice. Furthermore, administration of miR-15 or miR-16 mimics to NSG mice, in which these CLL cells were already engrafted and proliferating, caused significant tumor regression. Both observations are in line with the notion that miR-15 and miR-16 control the cell apoptotic apparatus and proliferative capacities. 17, 23, 24 No additive/synergistic effects were noted when miR-15 and miR-16 mimics were co-transfected, suggesting that the regulatory controls of the two miRNAs on the expression of other genes largely overlap, a consideration consistent with the notion that miR-15 and miR-16 interact with the same 3′-UTR region of BCL-2 mRNA. 24 Selective inhibition of miR-15 and miR-16 expression in CLL cells resulted in improved in vitro survival and a more robust expansion in NSG mice. 16 In contrast, enforced expression of miR-15 or miR-16 in cells retaining the capacity to express these miRNAs resulted in impaired in vitro survival or diminished expansion in NSG mice. Both findings provide further support for the regulatory role of intracellular miR-15/miR-16 concentrations in full-blown CLL 14, 23, 24, 32 ( Figure 5 ). The experimental design utilized here was intended to obtain a specific and selective inhibition or replacement of miR-15 and miR-16 without further influence of other gene segments such as Dleu2 or Dleu7, 39 the absence of which have been shown to synergize with that of miR-15 and miR-16 in CLL pathogenesis. Thus, the data demonstrate that low/ absent expression of miR-15 and miR-16 plays a crucial pathogenetic role per sè, in line with the observation that replacement of these miRNAs in NZB mice using suitable viral carriers blocks the expansion of CLL-like cells both in vivo and in vitro. 40 MiR-15 or miR-16 mimics did not apparently interfere with the function of T cells that are normally needed to support in vivo CLL cell growth. In the experiments where CLL cell growth in NSG mice was inhibited by pre-exposure to miR-15/miR-16 mimics in vitro (Figure 2 ), the T cells were added to the purified CLL cells following their in vitro exposure to these miRNAs. However, in experiments, where transfection was carried out in vitro on unfractionated cell suspensions, containing both T and CLL cells, before injection into mice, we observed an unaltered distribution pattern of T cells in the spleen of mice even in the presence a largely diminished proportion of B cells. Moreover, when mice were treated with miR-15 or miR-16 mimics in vivo, seemingly unaltered T cell proportions were observed surrounding the 'empty' areas, previously occupied by CLL cells (Figure 4) . Thus, inhibition of CLL cell growth in NSG mice presumably occurred through interference of the transfected mimics with the CLL cell survival/proliferating apparatus, rather than through an indirect action on the T cells promoting CLL cell growth. Whether or not progressive CLL cell death, induced by the transfected miRNA mimics in vivo, may lead to T cell immune-priming capable of causing further CLL cell elimination is presently unknown.
A final issue concerns the potential use of miR-15 and miR-16 for therapy. MiRNA mimics are effective on CLL cells growing in vivo and on CLL cells with additional chromosomal alterations; however, some results from both in vivo and in vitro experiments showed that the presence of TP53 gene mutations/deletions may render administration of the miR-15 and miR-16 mimics ineffective. This is expected, given the close interactions between miR-15 and miR-16, TP53 and the cluster of miR-34 genes in the regulation of cell survival/apoptosis. 41, 42 Nevertheless, not all cases with TP53 defects failed to respond to miRNA mimics treatment suggesting heterogeneity of functional TP53 alterations. These observations are being extended to additional cohorts of patients including more advanced stage/relapsed patients that more frequently harbor additional TP53 alterations. [43] [44] [45] [46] We provide proof of principle data supporting the potential use of miRNA mimics to block CLL clonal expansion. Additional miRNAs, other than miR-15 or miR-16, may become suitable therapeutic targets, as a number of studies have demonstrated anomalous expression of various miRNAs in CLL cells compared with normal cells. 11, 22, 30 Moreover, when certain miRNA are overexpressed, they can be targeted by miRNA inhibitors. 47 Several anomalies in miRNA expression have prognostic/predictive value for disease course and outcome, indicating a potential mechanistic role in the disease pathogenesis/progression. [22] [23] [24] 30, [48] [49] [50] [51] [52] Thus, the miRNA approach, especially if multiple miRNA mimics and inhibitors can be targeted, either alone or in combination with other drugs, may represent an additional therapeutical strategy. In connection with this, it should be noted that therapy with miR inhibition/replacement is being employed in a variety of experimental tumors. Moreover, there are many available studies on human tumors, some of which have reached the clinical stage I, with potentially promising results. 53 Thus, miR therapy may represent a 'real' tool in the future armamentarium of drugs usable in CLL, a disease that so far has escaped attempts toward a radical cure.
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